Arrowhead’s gene-silencing drugs cut visceral fat, liver fat
statnews.com••business
Key Points:
- Arrowhead Pharmaceuticals reported early Phase 1/2 trial results showing their gene-silencing drug candidate ARO-INHBE, combined with Eli Lilly’s Zepbound, led to a 9.4% weight loss in obese patients with diabetes after 16 weeks, outperforming Zepbound alone which resulted in a 4.8% loss.
- The combination therapy also significantly reduced harmful visceral fat by 23%, total fat by 15%, and liver fat by 77%, compared to reductions of 7%, 5%, and 20% respectively with Zepbound alone.
- These findings suggest ARO-INHBE may enhance the effectiveness of existing weight loss treatments, potentially intensifying competition among biotech companies developing
:max_bytes(150000):strip_icc()/GettyImages-22400154171-19eb2573d96647f8894478942b5721be.jpg)
